medigraphic.com
ISSN 2448-5640 (Print)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2023, Number 1

Next >>

Cir Card Mex 2023; 8 (1)

Surgical aortic valve replacement plus coronary artery bypass grafting remains as the current best option of treatment for severe aortic stenosis concomitant with stable coronary artery disease

García-Villarreal OA

Language: English
References: 24
Page: 1-4
PDF size: 163.26 Kb.


Text Extraction

In a recently published meta-analysis in the J Thorac Cardiovasc Surg, the authors compare two types of treatment for aortic stenosis concomitant with coronary artery disease, both of them with surgical indication. One is [SAVR (surgical aortic valve replacement) plus CABG (coronary artery bypass grafting)] being considered as the standard, and the other [TAVI (transcatheter aortic valve implantation) plus PCI (percutaneous coronary intervention)] being considered as useful.
In the cited meta-analysis, two randomized controlled trials and 6 observational studies were included, with a total number of 104, 220 patients. Out of them, 5004 underwent TAVI plus PCI, and 99, 216 received SAVR plus CABG. The weighted mean follow-up was 30.2 months.


REFERENCES

  1. Sakurai Y, Yokoyama Y, Fukuhara S, Takagi H, Kuno T. Complete transcatheterversus surgical approach to aortic stenosis with coronary artery disease: Asystematic review and meta-analysis. J Thorac Cardiovasc Surg. (2022):S0022-5223(22)00893-5. doi: 10.1016/j.jtcvs.2022.08.006.

  2. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for theManagement of Patients with Valvular Heart Disease: Executive Summary: AReport of the American College of Cardiology/American Heart Association JointCommittee on Clinical Practice Guidelines. Circulation. 2021;143(5): e35-e71.doi: 10.1161/CIR.0000000000000932.

  3. Vahanian A, Beyersdorf F, Praz F, et al; ESC/EACTS Scientific Document Group.2021 ESC/EACTS Guidelines for the management of valvular heart disease. EurHeart J. 2022;43(7):561-632. doi: 10.1093/eurheartj/ehab395.

  4. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guidelinefor Coronary Artery Revascularization: Executive Summary: A Report of theAmerican College of Cardiology/American Heart Association Joint Committeeon Clinical Practice Guidelines. Circulation. 2022;145(3):e4-e17. doi: 10.1161/CIR.0000000000001039.

  5. Neumann FJ, Sousa-Uva M, Ahlsson A, et al; ESC Scientific Document Group.2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J.2019;40(2):87-165. doi: 10.1093/eurheartj/ehy394.

  6. García-Villarreal OA, Heredia-Delgado JA, Lezama-Urtecho CA, et al.Declaración de Sociedad Mexicana de Cirugía Cardiaca, A. C. y el Colegio Mexicanode Cirugía Cardiovascular y Torácica, A. C. respecto a las nuevas guíasclínicas 2020 para el manejo del paciente con enfermedad valvular cardiaca dela American College of Cardiology/American Heart Association. Cir Card Mex2021; 6(3): 79-83.

  7. Dayan V, Garcia-Villarreal OA, Escobar A, et al. Latin American Associationof Cardiac and Endovascular Surgery statement regarding the recently releasedAmerican Heart Association/American College of Cardiology Guideline for theManagement of Patients with Valvular Heart Disease 2020. J Thorac CardiovascSurg. 2021;162(2):584-586. doi: 10.1016/j.jtcvs.2021.01.139.

  8. Braghiroli J, Kapoor K, Thielhelm TP, Ferreira T, Cohen MG. Transcatheter aorticvalve replacement in low risk patients: a review of PARTNER 3 and Evolutlow risk trials. Cardiovasc Diagn Ther. 2020;10(1):59-71. doi: 10.21037/cdt.2019.09.12.

  9. Muller Moran HR, Eikelboom R, Lodewyks C, Yan W, Zelentsov I, Arora RC, YamashitaMH. Two-year outcomes from the PARTNER 3 trial: where do we stand?Curr Opin Cardiol. 2021;36(2):141-147. doi: 10.1097/HCO.0000000000000813.

  10. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of TranscatheterAortic Valve Replacement. J Am Coll Cardiol. 2020;76(21):2492-2516. doi:10.1016/j.jacc.2020.09.595.

  11. García-Villarreal OA. What about current guidelines for coronary revascularization2018 ESC/EACTS for stable angina? Part I. Stable angina. Cir Card Mex2019; 4(4): 114-119.

  12. Gomes WJ, Albuquerque LC, Almeida RMS. New Revelations Ignite the EXCELAffair and Expose the Distortion of Science. Braz J Cardiovasc Surg.2020;35(5):I-III. doi: 10.21470/1678-9741-1-2020-0609.

  13. Gomes WJ, Albuquerque LC, Jatene FB, Leal JCF, Rocha EAV, Almeida RMS.The transfiguration of the EXCEL trial: exceeding ethical and moral boundaries.Eur J Cardiothorac Surg. 2020;58(1):30-34. doi: 10.1093/ejcts/ezaa121.

  14. García-Villarreal OA. The Excel trial and the current clinical guidelines for myocardialrevascularization: What do we need to know? Keep me in the loop! Part 2.Cir Card Mex; 2020; 5(3): 74-80.

  15. García-Villarreal OA. The 2018 ESC/EACTS guidelines for myocardial revascularization:a poisoned chalice? A mandatory major revision is now on the way. CirCard Mex 2021; 6(1): 1-2.

  16. Deb Cohen Surgeons withdraw support for heart disease advice.https://www.bbc.com/news/health-50715156

  17. Deb Cohen EXCEL Trial Controversy Continues as 'Imaginary' Universal Definitionof MI Data Published. https://www.medscape.com/viewarticle/934827

  18. Deb Coehn. Is the Tide Turning on the 'Grubby' Affair of EXCEL and the EuropeanGuidelines? https://www.medscape.com/viewarticle/939944

  19. https://www.eacts.org/eacts-responds-to-bbc-newsnights-investigation-on-the-excel-trial/

  20. Maron DJ, Hochman JS, Reynolds HR,et al; ISCHEMIA Research Group. InitialInvasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med.2020;382(15):1395-1407. doi: 10.1056/NEJMoa1915922.

  21. Gomes WJ, Dayan V, Myers PO, et al. The 2021 ACC/AHA/SCAI guideline forcoronary artery revascularization. A worldwide call for consistency and logic. JThorac Cardiovasc Surg (2022), doi: https:// doi.org/10.1016/j.jtcvs.2022.09.032.

  22. García-Villarreal OA. Left Main Coronary Artery Disease in the new 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A word of criticism.Cir Card Mex 2022; 7(2): 21-22.

  23. Yadava OP, Narayan P, Padmanabhan C, et al. IACTS position statement on"2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization": section7.1-a consensus document. Indian J Thorac Cardiovasc Surg. 2022;38(2):126-133. doi: 10.1007/s12055-022-01329-y.

  24. Sabik JF 3rd, Bakaeen FG, Ruel M, Moon MR, Malaisrie SC, Calhoon JH, GirardiLN, Guyton R; American Association for Thoracic Surgery and The Society ofThoracic Surgeons. The American Association for Thoracic Surgery and The Societyof Thoracic Surgeons Reasoning for Not Endorsing the 2021 ACC/AHA/SCAICoronary Revascularization Guidelines. Ann Thorac Surg. 2022;113(4):1065-1068. doi: 10.1016/j.athoracsur.2021.12.003.




2020     |     www.medigraphic.com